title: PPARγ: Welcoming the New Kid on the CML Stem Cell Block.
abstract: Recently, chronic myeloid leukemia (CML) patients already responding to treatment showed improved molecular responses with pioglitazone, presumably through PPARγ activation and CML stem cell eradication. Given data demonstrating deepening responses and successful treatment discontinuation with current therapy, the necessity for new therapies targeting CML stem cells to achieve cure is unclear.
authors.affiliation: Department of Pediatric Hematology/Oncology, University of California, San Francisco, San Francisco, CA 94143, USA.
authors.forename: Beth
authors.initials: B
authors.lastname: Apsel Winger
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA. Electronic address: neil.shah@ucsf.edu.
authors.forename: Neil P
authors.initials: NP
authors.lastname: Shah
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology* / Q000627:therapeutic use*; D001549:Benzamides / Q000008:administration & dosage*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology*; D014411:Neoplastic Stem Cells / Q000187:drug effects*; D047495:PPAR gamma / Q000819:agonists*; D010879:Piperazines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D045162:Thiazolidinediones / Q000008:administration & dosage*
chemical_list: D001549:Benzamides; D047495:PPAR gamma; D010879:Piperazines; D011743:Pyrimidines; D045162:Thiazolidinediones